A new Molecular Psychiatry article entitled “mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia” (2) is one point of arrival of years of extensive research linking metabotropic glutamate (mGlu) receptors to the pathophysiology and treatment of schizophrenia. Here, GRM5 is linked to schizophrenia.